Novavax 8-K: Financial Condition & Operations Update

Ticker: NVAX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1000694

Novavax Inc 8-K Filing Summary
FieldDetail
CompanyNovavax Inc (NVAX)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$0.01, $1.15 billion, $1.25 billion
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, regulation-fd, operational-update

TL;DR

**Novavax just dropped an 8-K hinting at new financial results and operational updates.**

AI Summary

Novavax, Inc. filed an 8-K on January 8, 2024, to disclose information under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). This filing indicates that the company is providing an update on its financial condition and operations, likely through a press release or investor presentation, which could contain new financial figures or strategic announcements. For investors, this matters because any new financial data or operational insights could significantly impact the stock's valuation and future prospects, especially given the company's focus on biological products.

Why It Matters

This filing signals that Novavax is releasing new financial or operational information, which could reveal whether the company is performing better or worse than expected, directly affecting investor confidence and stock price.

Risk Assessment

Risk Level: medium — The filing itself is procedural, but the undisclosed content it refers to could contain significant positive or negative news, creating uncertainty.

Analyst Insight

A smart investor would await the specific details of the 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' mentioned in this 8-K before making any investment decisions, as the actual content will determine the impact on Novavax's stock.

Key Players & Entities

  • NOVAVAX, INC. (company) — the registrant filing the 8-K
  • January 8, 2024 (date) — date of earliest event reported
  • 0-26770 (other) — Commission File Number
  • NVAX (other) — Trading Symbol for Common Stock
  • The Nasdaq Global Select Market (other) — exchange where Novavax Common Stock is registered

Forward-Looking Statements

  • Novavax will release a press release or hold an investor call detailing its financial results and operational updates. (NOVAVAX, INC.) — high confidence, target: 2024-01-08
  • The new information disclosed will impact NVAX stock price. (NVAX) — medium confidence, target: 2024-01-09

FAQ

What specific items did Novavax disclose in this 8-K filing?

Novavax, Inc. disclosed information under Item 2.02, 'Results of Operations and Financial Condition,' and Item 7.01, 'Regulation FD Disclosure,' as indicated in the filing dated January 8, 2024.

What is the primary purpose of an 8-K filing for 'Results of Operations and Financial Condition'?

An 8-K filing under Item 2.02, 'Results of Operations and Financial Condition,' is typically used to announce material information regarding a company's financial performance, such as earnings releases or updates on financial guidance, as seen in Novavax's filing on January 8, 2024.

What does 'Regulation FD Disclosure' (Item 7.01) imply for Novavax?

Item 7.01, 'Regulation FD Disclosure,' means Novavax is making public information that was previously shared selectively with certain individuals (like analysts or institutional investors) to ensure fair and broad dissemination to all investors, as indicated in their January 8, 2024 filing.

What is Novavax's trading symbol and where is its common stock registered?

Novavax, Inc.'s common stock trades under the symbol NVAX and is registered on The Nasdaq Global Select Market, according to the 8-K filing on January 8, 2024.

What is the state of incorporation for Novavax, Inc.?

Novavax, Inc. is incorporated in Delaware, as stated in the 8-K filing dated January 8, 2024.

Filing Stats: 1,200 words · 5 min read · ~4 pages · Grade level 12.2 · Accepted 2024-01-08 09:25:15

Key Financial Figures

  • $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se
  • $1.15 billion — ses, which is anticipated to be between $1.15 billion and $1.25 billion. The Company is in t
  • $1.25 billion — cipated to be between $1.15 billion and $1.25 billion. The Company is in the process of fina

Filing Documents

02 Results of Operations and Financial

Item 2.02 Results of Operations and Financial Condition On January 8, 2024, Novavax, Inc. (the "Company") provided an update for investors in which it reaffirmed its guidance for full year 2023 combined research and development and selling, general and administrative expenses, which is anticipated to be between $1.15 billion and $1.25 billion. The Company is in the process of finalizing its financial results for the year ended December 31, 2023, and the foregoing preliminary financial data is based on available information to date. This financial data for the year ended December 31, 2023 is preliminary and may change. This preliminary financial data has been prepared by, and is the responsibility of, the Company's management. Ernst & Young LLP, the Company's independent registered public accounting firm, has not audited, reviewed, compiled or performed any procedures with respect to this preliminary financial data, nor have any other independent accountants. Accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto. The Company's actual results for this period may differ from the foregoing preliminary financial data and such changes could be material. In addition, this preliminary financial data should not be viewed as a substitute for full financial that will be material to investors will be provided in these financial statements, and, accordingly, investors should not place undue reliance on the limited preliminary information being provided herein. This Current Report on Form 8-K includes forward-looking statements including statements regarding the Company's current expectations, financial results and anticipated results of operations, including financial guidance for full year 2023 and 2024. Generally,

forward-looking statements can be identified through the use of words or phrases such as "could," "will," "would,"

forward-looking statements can be identified through the use of words or phrases such as "could," "will," "would," "can," "estimate," "continue," "ongoing," "consider," "anticipate," "intend," "seek," "plan," "project," "expect," "should," "prepare", or "aim", the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements. Such risks and uncertainties include, among others, that the Company's full financial statements for the year ended December 31, 2023 prepared in accordance with U.S. generally accepted accounting standards may differ materially from the preliminary and unaudited amounts reported herein and other risks and uncertainties are identified under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, in subsequent Quarterly Reports on Form 10-Q and in any subsequent filings with the Securities and Exchange Commission. Further, any forward-looking statement speaks only as of the date when it is made, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. New factors emerge from time to time, and it is not possible for the Company to predict which factors will arise. In addition, the Company cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

01

Item 7.01. Regulation FD Disclosure. On January 8, 2024, the Company provided an update for investors at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, presenting information relating to certain strategic and business updates (the "Investor Presentation"), which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. A copy of the Investor Presentation will also be accessible on the Company's website at www.novavax.com under "Latest Investor Presentation." Cautionary Note Regarding Forward-Looking cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the Investor Presentation regarding these forward-looking statements. The information in Item 2.02 and Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing. In addition, the contents of the Company's website are not incorporated by reference into this Current Report on Form 8-K and you should not consider information provided on the Company's website to be part of this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Investor Presentation of Novavax, Inc. 104 Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Novavax, Inc. Date: January 8, 2024 By: /s/ Mark Casey Name: Mark Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.